PDE5 Inhibitor Side Effects: Headache, Flushing, Vision Changes, and the Rare Risks That Matter

Phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil, tadalafil, and vardenafil are the first-line oral treatment for erectile dysfunction, and they are among the most widely prescribed medications in men's health. Understanding PDE5 inhibitor side effects is part of using these medications well: most adverse effects are predictable extensions of how the drugs work, they are usually mild and short-lived, and a small number of rare events warrant prompt medical attention. This review summarizes what randomized trials and large observational studies show about common reactions, how the individual drugs differ, and how the rare risks compare with their reputation.

Why PDE5 Inhibitors Cause Side Effects

An erection depends on nitric oxide signaling. Sexual stimulation releases nitric oxide in penile tissue, which raises cyclic guanosine monophosphate (cGMP) and relaxes the smooth muscle of the corpora cavernosa. PDE5 breaks cGMP down. By slowing that breakdown, PDE5 inhibitors allow the vascular response to sexual stimulation to build and persist.

PDE5 is not confined to the penis. It is present in vascular smooth muscle throughout the body, in the nasal mucosa, and in the gastrointestinal tract, including the lower esophageal sphincter. The same cGMP-enhancing effect that supports penile blood flow also dilates vessels in the head and face and relaxes the esophageal sphincter. That explains the most frequently reported reactions: headache, facial flushing, nasal congestion, and indigestion ^[2].

A second group of effects reflects imperfect selectivity. PDE5 inhibitors can partially inhibit related isoenzymes. Sildenafil and, to a lesser degree, vardenafil cross-react with PDE6, an enzyme in retinal photoreceptors, which is the likely basis for a transient color tinge and light sensitivity. Tadalafil has greater activity against PDE11, found in skeletal muscle, and is more often associated with back pain and muscle aches, which typically appear 12 to 24 hours after a dose ^[2].

The Most Common PDE5 Inhibitor Side Effects

Across placebo-controlled trials, the adverse events reported most consistently are:

Headache, the single most common complaint, generally mild to moderate
Flushing of the face, neck, or chest, caused by cutaneous vasodilation
Dyspepsia or reflux, related to relaxation of the lower esophageal sphincter
Nasal congestion, from vasodilation in the nasal mucosa
Back pain and myalgia, seen predominantly with tadalafil
Dizziness, usually reflecting a modest fall in blood pressure
Visual disturbances, such as a blue-green color tinge or increased light sensitivity, seen predominantly with sildenafil at higher doses

These effects are dose-related and usually resolve as the drug is cleared, and some men notice them less with continued use. Their duration tends to follow each drug's pharmacokinetics. Effects from sildenafil, which has a half-life of about four hours, generally fade within hours, while the longer half-life of tadalafil (about 17.5 hours) means that aches or congestion may linger into the next day ^[2]. For more on timing, see our review of how long ED medications last.

In clinical trials, discontinuation because of adverse events has generally been low. When men stop PDE5 inhibitor therapy, the reasons more often involve cost, relationship factors, unmet expectations, or incorrect use than intolerable side effects.

How Sildenafil, Tadalafil, and Vardenafil Compare

The most rigorous comparison of tolerability across agents comes from a trade-off network meta-analysis published in European Urology. Chen and colleagues pooled 82 randomized trials (47,626 patients) for efficacy and 72 trials (20,325 patients) for adverse events, comparing agents at their usual starting doses ^[1].

The analysis identified a clear efficacy–tolerability trade-off:

Sildenafil 50 mg showed the greatest global efficacy but also the highest overall rate of adverse events.
Tadalafil 10 mg had intermediate efficacy with the lowest overall adverse event rate.
Vardenafil 10 mg and avanafil 100 mg had overall adverse event rates similar to sildenafil 50 mg, with markedly lower global efficacy.

The authors concluded that men who prioritize efficacy may favor sildenafil, while men who want to optimize tolerability may do better with tadalafil ^[1]. These are population averages. Individual responses vary considerably, and a man who experiences troublesome headaches on one agent may tolerate another well.

Adjusting Treatment When Side Effects Occur

For bothersome but non-dangerous side effects, several approaches may help, always in discussion with the prescribing clinician:

Dose adjustment. Because most adverse effects are dose-related, a lower dose may preserve benefit while reducing headache, flushing, or visual effects.
Switching agents. Given differences in isoenzyme selectivity, a man with visual symptoms on sildenafil may do better on tadalafil, while one with back pain on tadalafil may tolerate a shorter-acting agent.
Hydration and alcohol moderation. Adequate fluid intake and limited alcohol may reduce headache and dizziness.
Meal timing. A heavy, high-fat meal delays sildenafil and vardenafil absorption, which can tempt men to take extra doses. Tadalafil absorption is largely unaffected by food.
Never doubling up. Taking more than the prescribed dose, or combining products from different sources, increases side-effect risk without reliable gains in efficacy.

Vision and Hearing: Putting the Rare Risks in Context

Few PDE5 inhibitor safety questions attract as much attention as vision loss. Nonarteritic anterior ischemic optic neuropathy (NAION) is a rare condition in which reduced blood flow damages the optic nerve, causing sudden, usually painless loss of vision in one eye. It occurs most often in men over 50 with vascular risk factors and a structurally crowded optic disc, the same population in which erectile dysfunction is common.

The strongest study of timing comes from Campbell and colleagues, who used a case-crossover design across 102 ophthalmology centers in the United States and Europe. Among 43 adjudicated definite NAION cases with recent PDE5 inhibitor exposure, the odds of NAION onset were approximately doubled within five drug half-lives of a dose compared with other periods (OR 2.15; 95% CI 1.06–4.34). The authors translated this into absolute terms: weekly PDE5 inhibitor use would add roughly three NAION cases per 100,000 men aged 50 and older each year ^[3].

Larger population data offer reassurance about broader ocular risk. A 2023 analysis in the Journal of Sexual Medicine examined insurance claims for 1,938,262 men with an erectile dysfunction diagnosis, of whom 615,838 were treated with PDE5 inhibitors. After adjustment for age, diabetes, hypertension, obesity, coronary artery disease, sleep apnea, and other factors, PDE5 inhibitor use was not associated with serous retinal detachment, retinal vascular occlusion, ischemic optic neuropathy, or any ocular event compared with men who had erectile dysfunction and used other treatments ^[4].

Taken together, these data suggest that serious ocular events are rare and that any association with PDE5 inhibitors is small in absolute terms. Even so, sudden vision loss in one or both eyes after taking a PDE5 inhibitor requires stopping the medication and seeking immediate medical evaluation. Men with a prior episode of NAION should discuss whether these drugs are appropriate before using them. Sudden decrease or loss of hearing, sometimes with tinnitus or dizziness, appears in product labeling as a rare reported event and warrants the same response.

Priapism, Blood Pressure, and Interactions That Require Supervision

Priapism. An erection lasting more than four hours is a medical emergency. It is rare with PDE5 inhibitors used as directed, but untreated priapism can cause permanent tissue damage. Risk is higher in men with sickle cell disease, certain blood disorders, or anatomical abnormalities of the penis, and in men who combine PDE5 inhibitors with other erectogenic treatments.

Blood pressure. PDE5 inhibitors are mild systemic vasodilators and produce a small, usually asymptomatic reduction in blood pressure. This becomes clinically important when they are combined with other drugs that lower blood pressure. Organic nitrates, including nitroglycerin and isosorbide, are absolutely contraindicated because the combination can cause severe hypotension, and the soluble guanylate cyclase stimulator riociguat carries the same restriction. Alpha-blockers used for prostate symptoms or hypertension can be combined only with careful dosing and physician oversight. Our review of PDE5 inhibitor drug interactions covers these combinations in detail.

Metabolic interactions. PDE5 inhibitors are cleared mainly by the liver enzyme CYP3A4. Strong inhibitors of this enzyme, such as certain antifungals, macrolide antibiotics, and HIV protease inhibitors, can substantially raise drug levels and amplify side effects, which may require dose reduction. Heavy alcohol intake adds to the blood-pressure-lowering effect and increases the likelihood of dizziness and headache.

Cardiac fitness for sexual activity. Sexual activity itself carries a modest cardiovascular workload. Men with unstable angina, a recent heart attack or stroke, uncontrolled arrhythmias, or poorly controlled blood pressure should have their cardiovascular status assessed before starting treatment.

Sourcing matters as well. Products sold without a prescription, including many so-called herbal sexual enhancement supplements, have repeatedly been found to contain undeclared or unpredictable amounts of PDE5 inhibitors, bypassing the screening that prevents dangerous interactions. Related topics on circulation, medications, and sexual health are covered across our blog.

Conclusion

PDE5 inhibitor side effects are, for most men, predictable and manageable. Headache, flushing, nasal congestion, and indigestion reflect the same vasodilatory mechanism that supports erectile function, while back pain and visual color changes reflect differences in isoenzyme selectivity between drugs. Network meta-analysis suggests a genuine trade-off between efficacy and tolerability, with tadalafil showing the lowest overall adverse event rate at starting doses. Serious events such as NAION, sudden hearing loss, and priapism are rare, and large population data have not shown a consistent increase in ocular adverse events among users. The risks that matter most are largely preventable through proper screening: avoiding nitrates, reviewing interacting medications, and assessing cardiovascular fitness before treatment begins.

If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans, including Red Pill, starting with a free online assessment at questionnaire.getonyxmd.com.

These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.

References

Chen L, Staubli SE, Schneider MP, Kessels AG, Ivic S, Bachmann LM, Kessler TM. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis. European Urology. 2015;68(4):674-680. doi:10.1016/j.eururo.2015.03.031
Huang SA, Lie JD. Phosphodiesterase-5 (PDE5) inhibitors in the management of erectile dysfunction. P&T. 2013;38(7):407-419. PMC3776492
Campbell UB, Walker AM, Gaffney M, et al. Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors. Journal of Sexual Medicine. 2015;12(1):139-151. doi:10.1111/jsm.12726
Belladelli F, Li S, Zhang CA, et al. Use of phosphodiesterase 5 inhibitors is not associated with ocular adverse events. Journal of Sexual Medicine. 2023;20(12):1399-1406. doi:10.1093/jsxmed/qdad137